Dupont Capital Management Corp bought a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 8,567 shares of the specialty pharmaceutical company’s stock, valued at approximately $450,000. Dupont Capital Management Corp owned 0.07% of ANI Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of ANIP. Dimensional Fund Advisors LP increased its stake in shares of ANI Pharmaceuticals by 91.1% during the second quarter. Dimensional Fund Advisors LP now owns 339,268 shares of the specialty pharmaceutical company’s stock valued at $15,878,000 after buying an additional 161,743 shares during the period. First Manhattan Co. increased its stake in shares of ANI Pharmaceuticals by 35.3% during the second quarter. First Manhattan Co. now owns 376,395 shares of the specialty pharmaceutical company’s stock valued at $17,615,000 after buying an additional 98,300 shares during the period. Bank of America Corp DE increased its stake in shares of ANI Pharmaceuticals by 25.5% during the first quarter. Bank of America Corp DE now owns 197,224 shares of the specialty pharmaceutical company’s stock valued at $9,764,000 after buying an additional 40,111 shares during the period. Vanguard Group Inc. increased its stake in shares of ANI Pharmaceuticals by 8.1% during the second quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock valued at $22,322,000 after buying an additional 35,722 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of ANI Pharmaceuticals by 7.0% during the second quarter. Renaissance Technologies LLC now owns 297,400 shares of the specialty pharmaceutical company’s stock valued at $13,918,000 after buying an additional 19,400 shares during the period. 56.48% of the stock is currently owned by hedge funds and other institutional investors.

ANIP has been the topic of several research analyst reports. Canaccord Genuity initiated coverage on ANI Pharmaceuticals in a research note on Monday, July 31st. They set a “buy” rating and a $60.00 target price on the stock. Zacks Investment Research raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 target price on the stock in a research note on Tuesday, November 7th. ValuEngine raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 4th. Finally, BidaskClub raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 18th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. ANI Pharmaceuticals has an average rating of “Buy” and an average target price of $68.25.

ILLEGAL ACTIVITY WARNING: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.dailypolitical.com/2017/11/13/dupont-capital-management-corp-buys-new-position-in-ani-pharmaceuticals-inc-anip.html.

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) opened at $61.90 on Monday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 3.45. ANI Pharmaceuticals, Inc. has a 1 year low of $42.23 and a 1 year high of $65.81. The firm has a market capitalization of $721.32, a P/E ratio of 18.48 and a beta of 2.85.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The company had revenue of $48.16 million for the quarter, compared to analyst estimates of $48.12 million. During the same period in the previous year, the company posted $1.09 earnings per share. The firm’s revenue was up 25.0% on a year-over-year basis. research analysts predict that ANI Pharmaceuticals, Inc. will post 3.59 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.